MNPR — Monopar Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $368.94m
- $228.54m
Annual cashflow statement for Monopar Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -9.1 | -10.5 | -8.4 | -15.6 | -13.7 |
| Non-Cash Items | 1.47 | 1.64 | 1.9 | 5.69 | 4.12 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.318 | 1.65 | -1.35 | 3.49 | -2.61 |
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -7.32 | -7.23 | -7.86 | -6.4 | -12.2 |
| Other Investing Cash Flow Items | — | -4.92 | 4.93 | -14.3 | -63.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | — | -4.92 | 4.93 | -14.3 | -63.5 |
| Financing Cash Flow Items | -0.063 | -0.077 | -0.047 | -0.104 | -1.13 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 10.9 | 0.033 | 2.03 | 59.3 | 91.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.57 | -12.1 | -0.92 | 38.6 | 16 |